(MGNX) MacroGenics - Ratings and Ratios

MacroGenics, Inc. (NASDAQ:MGNX) is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of antibody-based therapeutics, primarily for the treatment of cancer. The companys lead product, MARGENZA (margetuximab-cmkb), is an FDA-approved HER2 receptor antagonist used in combination with chemotherapy for adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The drugs approval underscores MacroGenics focus on addressing unmet needs in oncology.

MacroGenics pipeline is heavily weighted toward immuno-oncology, with a focus on innovative antibody-based approaches. Key candidates include MGC018, an antibody drug conjugate (ADC) targeting B7-H3, a protein overexpressed in various solid tumors, and MGD024, a bispecific CD123 × CD3 DART molecule designed to treat hematologic malignancies with a reduced risk of cytokine-release syndrome. The company also has a robust portfolio of checkpoint inhibitors, including Lorigerlimab (PD-1/PD-L1), Retifanlimab (PD-1), and Tebotelimab, a tetravalent DART molecule targeting PD-1 and lymphocyte-activation gene 3 (LAG-3). These programs highlight MacroGenics commitment to advancing next-generation immunotherapies.

Additionally, MacroGenics is exploring non-oncology indications, such as Teplizumab for type 1 diabetes and PRV-3279, a CD32B × CD79B DART molecule for autoimmune diseases. The company has established collaborations with major biopharma players, including Incyte Corporation, Zai Lab Limited, I-Mab Biopharma, and Janssen Biotech, Inc., to accelerate the development and commercialization of its pipeline. Founded in 2000 and headquartered in Rockville, Maryland, MacroGenics has built a reputation for innovation in antibody engineering and clinical development.

Ticker Symbol: MGNX
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Biotechnology

Average Volume 20d: 685414
Last Price: 2.32
SMA 20: 2.61
SMA 50: 2.95
SMA 200: 3.68
ATR: 0.18

Market Cap: 154.40M USD
P/E: 0.00
P/E Forward: 0.00
P/B: 1.29
P/S: 1.09
RoE: -81.30

Based on the technical and fundamental data, MacroGenics, Inc. (NASDAQ:MGNX) is expected to face headwinds in the next three months. The stocks price is below its SMA 20, SMA 50, and SMA 200, indicating bearish momentum. The average trading volume remains moderate, and the ATR suggests low volatility. Fundamentally, the companys negative P/E ratio and high P/B ratio relative to its peers may raise concerns among investors. While the pipeline remains promising, the lack of near-term catalysts and the challenging broader market conditions for biotechnology stocks may limit upside potential in the short term. Analysts anticipate a sideways to slightly downward trend, with potential price targets ranging between $2.00 and $2.50 over the next quarter.